



Viral Agents of Gastroenteritis : How Important are they?


Roger I. Glass, M.D., Ph.D.
Director, Fogarty International Center
Associate Director for International Research, NIH

Dijon
June 14, 2007




JOHN E. FOGARTY
INTERNATIONAL
CENTER





**Everyone
Poops**


Estimated global distribution of the 2.2 million annual childhood deaths caused by diarrhea



1 dot = 5,000 deaths


20% of deaths < 5 yrs

The Estimated Burden of Gastroenteritis in the United States



The "Diagnostic Void"


Survey of >30,000 specimens from 10 hospitals



ref: L. Slutsker, 1997



Etiology of 7,458 Outbreaks of Gastroenteritis Reported to CDC, 1973-1987




Unknown (62%)

ref: Bean & Griffin, 1990




Viral Agents of Gastroenteritis


Rotavirus








Adenovirus



Astrovirus



Calicivirus - NLV



Calicivirus - SLV


Torovirus

Picobirnavirus

Enterovirus 22


Noroviruses (a.k.a. Norwalk-like Viruses, human caliciviruses)

- Identified by electron microscopy (Kapikian)-1972
- Do not grow in cell culture; no animal model
- Commercial detection assays under development
- Molecular detection by RT-PCR
- Many different genotypes





- Most common cause of outbreaks of nonbacterial acute gastroenteritis

Norovirus Detection by RT-PCR/EIA




Stool cup-to-Sequence Detection & Characterization of NLVs






Maryland Oyster Tracking



Nucleotide Relatedness of SRSVs 104 bp within RNA Polymerase





Over a 3 day period,
one sick fisherman
contaminated 23,000
bushels of oysters sold
in about 14 states with a
single strain of norovirus

Vomiting bug cases at record high



The signs have changed to reflect market

Country Studies

Country Profiles The number of cases of the winter vomiting bug doubled over the last 12 months to reach their highest ever level, official figures have revealed.

1500

- 22 Jan 02 | T-Z
Winter vomiting virus
 - 23 Jan 02 | Health
Gastric virus causing widespread misery
 - 19 Nov 02 | Wales
Hospital identifies winter bug

Internet Books

- ## **Public Health Laboratory Service Norwalk-like virus information**

The BBC is not responsible for the content of external Internet sites.

[IdeasWithAction.com](http://www.IdeasWithAction.com)

- 'Cloned baby' DNA test delayed**
NHS moves to cut
electrics' hours

Outbreaks aboard Cruise Ships, 2005




- **14 outbreaks on 10 ships**
- **Some repeated after cleanup**
- **By sequence, some linked to common sources**
- **Overcrowding –major risk**
- **Multiple modes of spread**
 - Food, person- to-person

International Outbreaks of Norwalk like Virus



Enhanced Foodborne Outbreak Surveillance: CA, MD, TN; 2001-2002



- Active Outbreak Detection
- Aggressive sample collection (In-home kits)
- Comprehensive pathogen testing

Sporadic Norovirus Gastroenteritis in Adults: Emergency Department Patients

- 3 FoodNet sites (CT, NY, OR)
- 364 subjects enrolled
- 152 subjects with stool sample tested for all pathogens
- ***Norovirus most common pathogen detected***

Pathogen	No. positive (%)
Viruses	49 (32%)
Norovirus	30 (20%)
Rotavirus	18 (12%)
Any bacteria	21 (14%)
Any parasite	3 (2%)
Any pathogen	73/152 (48%)
No pathogen	79/152 (52%)




The Global Challenge



Are noroviruses a problem in the developing world ?



Etiology of Severe Diarrhea in Peruvian Children




U. Parasher, 2003


Will this translate into mortality?



Etiology of Diarrhea in Finnish Children



Research Challenges




Diagnostics
Receptors
Vaccines
Cell Culture
Animal models

A Kapikian
B,C,D Prasad




Histoire Naturelle des Infections à Rotavirus



- La cause la plus frequente de diarrhee severe chez l'enfant
- Touchera tous les enfants avant l'age de 5 ans
- Un virus “Democratique”
- La premiere infection est symptomatique
- Immunite naturelle est bonne
- Peu de souches circulantes
- L'amelioration de conditions d'hygiene n'influence pas l'infection

Distribution des 600,000 deces annuel dus au rotavirus



Parashar, 2005

1 dot = 1000 deaths



Importance de Rotavirus aux US

Risk

Events

$1 : 10^6$

20-40 Deaths

$1 : 80$

60-70,000 Hospitalizations

$1 : 7$


500,000 Outpatient visits

$1 : 0.9$


3.2 Million episodes

Cost: \$400 M medical; >\$1 B total






Diarrhea-associated hospitalizations by month & age among U.S. children < 5 years, 1979-1997



Genotypes de Rotavirus (1993-2003)



Rare or regionally common strains (23 strains total): P[4]G1 (1.3%), P[6]G2 (0.8%), P[6]G1 (0.6%), P[6]G8 (0.6%), P[4], G3 (0.5%)



INFECTIOUS DISEASES IN CHILDREN

Circulation: 25,000
February 1997

Rotavirus vaccine shown to be cost effective

New Vaccine
Passes Test
For Disease
In Children

HEALTHCARE REVIEW

Southern New England Edition (Massachusetts, Connecticut & Rhode Island)
Circulation: 52,000
Date: February/March 1997

Rotavirus: Affecting children
and healthcare costs across the globe

by Alan C. Dunn, MD, FRCR

NEWS VS. HISTORY

Honor due to Kapikian

QUESTION: What Washington now figures better or more and gets more attention during the year and the public — Virginia Kennedy, Komella Starr or Albert Kapikian? Now consider this: Which of those people is likely to have a more profound effect on the world?

on young ones to hospitals each year and killing about 1 million children in other countries. Some think that the virus will wipe out, relatively effortlessly, but it should greatly increase survival of the weak and the disabled who often become deadly.

Winston-Salem Journal
September 8, 1995

The Virginian-Pilot

New vaccine may tame
common childhood virus

The New York Times

F.D.A. Approves Vaccine for Childhood Diarrhea

By THE ASSOCIATED PRESS

WASHINGTON -- The Food and Drug Administration Monday approved the first vaccine against a leading cause of childhood diarrhea, a virus that hospitalizes 55,000 American children a year and kills one million in other countries.

Vaccine offers
way to prevent
child diarrhea

Pediatric News

Circulation: 18,418
Date: November 1996

Rotavirus Vaccine
Cuts Diarrhea Hospitalizations

CDC

Rhesus Rotavirus Vaccine

- Vaccins vivant oral
- 3 doses --2,4,6 mois
- Bien tolere
- Efficacite – >90% contre hospitalisations
- Efficacite evallee au Venezuela
- Acceptabilite rapide aux USA malgre le prix
(\$38/dose)



Calendrier Vaccinal aux USA --1999

Age ► Vaccine ▼	Birth	1 mo	2 mos	4 mos	6 mos	12 mos	15 mos	18 mos	4-6 yrs	11-12 yrs	14-16 yrs
Hepatitis B	Hep B									Hep B	
Diphtheria, Tetanus, Pertussis		Hep B		Hep B					DTaP	Td	
<i>H. influenzae</i> type b			DTaP	DTaP	DTaP			DTaP			
Polio			Hib	Hib	Hib	Hib	Hib		Polio		
Rotavirus	Rv	Rv	IPV	IPV	Rv						
Measles, Mumps, Rubella						MMR			MMR	MMR	
Varicella						Var				Var	



MMWR


MORBIDITY AND MORTALITY
WEEKLY REPORT

- 577 Intussusception Among Recipients of Rotavirus Vaccine — United States, 1998–1999
- 582 Outbreak of *Salmonella* Serotype Muenchen Infections Associated with Unpasteurized Orange Juice — United States and Canada, June 1999
- 585 Progress Toward Measles Elimination — Southern Africa, 1996–1998
- 590 Recommendations of the Advisory Committee on Immunization Practices: Revised Recommendations for Routine Poliomyelitis Vaccination

Intussusception Among Recipients of Rotavirus Vaccine — United States, 1998–1999

On August 31, 1998, a tetravalent rhesus-based rotavirus vaccine (RotaShield®*), Wyeth Laboratories, Inc., Marietta, Pennsylvania) (RRV-TV) was licensed in the United States for vaccination of infants. The Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics, and the American Academy of Family Physicians have recommended routine use of RRV-TV for vaccination of healthy infants (1,2). During September 1, 1998–July 7, 1999, 15 cases of intussusception (a bowel obstruction in which one segment of bowel becomes enfolded within another segment) among infants who had received RRV-TV were reported to the Vaccine Adverse Event Reporting System (VAERS). This report summarizes the clinical and epidemiologic features of these cases and preliminary data from ongoing studies of intussusception and rotavirus vaccine.

Interval between Vaccine and Intussusception



Murphy TV, et al, 2001




Evaluation du risque d'invagination intestinale apres RotaShield®

Study	Author	Risk	Excess Cases for US
Preliminary Data	Livengood-NIP	1 in 2500	1600
Reassessment	Livengood-NIP		888
Case Series	Murphy-NIP	1 in 4670	785
Case Control	Murphy-NIP	1 in 9474	361
Cohort Study	Kramarz-NIP	1 in 11,073	316
Ecologic Studies	Chang-NYS	<1 in 17 000	200
	Simonsen-NIH all infants	-11%	0
	45-210 days	1 in 28,000	122




Taux d'incidence et nombre d'hospitalisations pour invagination intestinal par age (mois)

VSD, 1991-1997




*80% des les inv. int. chez les enfants age de plus de 3 mois
lors de la premiere dose*

The next generation of rotavirus vaccines



GSK Bio
Rotarix



Merck
RotaTeq

Human-Bovine Reassortant Rotavirus Vaccine - RotaTeq® (Merck)

- *Pentavalent*
- *Liquid vaccine with buffer, stabilizer*
- *3 doses, 2ml/dose,*
- *easy to administer*
- *Grows poorly -high dose (10^{7-8}), low shedding*



Clinical Trials of Rotateq

	Vac / Placebo	Outcome	Vac Placebo	Efficacy (95%CI)
U.S., Finland	2834/2839	Any	83 / 315	74 (67-80)
		Severe	1 / 51	98 (88-100)
U.S.	650 / 650	Any	15 / 54	73 (51-86)
		Mod/sev	10 / 42	76 (52-89)
		Severe	0 / 6	100 (13-100)

GSK Attenuated Human Rotavirus Vaccine, Rotarix®

- *Monovalent*
- *Lyophilized vaccine,
needs reconstitution*
- *2 doses, 1 ml/dose*
- *Grows well -low dose
($10^{5.8}$); high shedding
(>50%)*



Clinical Trials of Rotarix

	Vac/Placebo	Outcome	Vaccine Placebo	Efficacy (95%CI)
Finland,	245 / 123	Any	13 / 23	72 (42-87)
		Severe	2 / 10	85 (42-97)
Brazil, Mexico, Venezuela	464 / 454	Any	15 / 49	70 (46-84)
		Severe.	5 / 3434	86 (63-96)
Latin America	10,159 / 10,010	Severe	NA	85 (72-92)
		Hosp.		85 (77-94)

Efficacy of Rotarix

- 63,225 infants in 11 Latin American countries
- ~20,169 followed for severe GE until 12 mo.
- Efficacy - severe RVGE 85%
 G1 disease 92%
 non-G1 75%
 (G2 ~50%

All GE hospitalizations 41%

Safety from Intussusception


	Followup	Vac/ Placebo	IS cases	
			Vac/Pl	
Rotarix	31 days	31,500/	Dose 1	1 / 2
		31,500	Dose 2	5/5
			Total	6 / 7
RotaTeq	42 days	35,150	Dose 1	0 / 1
		35,150	Dose 2	4/ 1
			Dose 3	2/ 3
			Total	6/ 5

Was Intussusception due to Rotashield alone ?

CDC Advisory Committee on Immunization Practices (ACIP) –Feb. 2006

Draft-- Recommendations for Pentavalent Bovine-Human Rotavirus Vaccine (PRV)

- Routine immunization of infants
- 3 doses at 2, 4, and 6 months of age
- Dose 1 between 6-12 weeks of age
- All doses by 32 weeks of age
- 4-10 week interval between doses



6



Status of Rotavirus vaccine licensure, as of 15 March 2007

GSK Rotarix® licensure (88 countries):

<i>WHO Region</i>	<i>Countries that have licensed Rotarix®</i>	
Americas	22	<i>Argentina, Aruba, Bolivia, Brazil, Chile, Colombia, Costa Rica, Curaçao, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Suriname, Trinidad/Tobago, Venezuela</i>
Africa	17	<i>Burkina Faso, Cameroun, Central African Republic, Congo, DR Congo, Guinea, Ivory Coast, Kenya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Nigeria, Senegal, South Africa, Togo</i>
Europe	31	<i>Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK</i>
Middle East	8	<i>Bahrain, Morocco, Oman, Pakistan, Qatar, Saudi Arabia, UAE, Yemen</i>
Southeast Asia	3	<i>Bangladesh, Sri Lanka, Thailand</i>
Western Pacific	7	<i>Australia, Hong Kong, Malaysia, New Zealand, Philippines, Singapore, Taiwan</i>

From: Robin Bielik, PATH



Status of Rotavirus vaccine licensure, as of 1 March 2007

Merck RotaTeq™ licensure (47 countries):

WHO Region	Countries that have licensed RotaTeq®	
Americas	12	<i>Argentina, Canada, Curaçao, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Perú, Puerto Rico, USA</i>
Africa	6	<i>DRCongo, Guinea, Kenya, Niger, Rwanda, Togo</i>
Europe	26	<i>Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Turkey, UK</i>
Middle East	0	
Southeast Asia	0	
Western Pacific	3	<i>Australia, Hong Kong, Taiwan</i>

From: Robin Bielik, PATH




Les vaccins vivant oraux-- seront ils efficaces dans les pays en développement ?


- OPV Less immunogenic/more doses needed for children in India (*T. Jacob Johns*)
 - Cholera (Oralchol) Less immunogenic/higher titer needed in Thai/Indonesian studies (*Mike Levine*)
 - Oral RV
 - RIT Failed in Africa/Peru
 - WC3 Failed in Africa
 - RRV Lower efficacy in Peru/Brazil
 - GSK Being tested in S.Africa/Bangladesh




Timelines




Reseau de rotavirus en Asie 2001-2003



Reseaux regionaux de surveillance de rotavirus




Vaccins rotavirus - “le fruit le plus mur” des vaccins en développement



- disease burden is large & global
- principles to develop vaccines are well established
- extensive past experience with clinical trials
- achievable in 5-7 years
- impact of vaccine should be measurable within one year

Celles qui font peur et celles qui tuent!





Utilisera-t-on le vaccin Rotavirus en Europe?

*Quelles seront les facteurs clés
de décision ?*